Depomed, Inc. (NASDAQ: DEPO), a specialty pharmaceutical company, is devoted to enhancing existing pharmaceutical products. To date, the company has brought two products to market and has developed a pipeline with late-stage product opportunities designed to address common medical conditions. Depomed’s core delivery technology, AcuForm, is a patented, polymer-based technology that improves delivery through gastric retention. For further information, visit the Company’s web site at www.depomedinc.com.
- 17 years ago
QualityStocks
Depomed, Inc. (NASDAQ: DEPO)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…